Common Equity: The sum of all common equity items.
Inhibikase Therapeutics, Inc. (IKT) had Common Equity of $72.90M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-11.93M |
|
-- |
|
-- |
|
$12.77M |
|
$-12.77M |
|
$0.84M |
|
$-11.93M |
|
$-11.93M |
|
$-11.93M |
|
$-11.93M |
|
$-11.93M |
|
$-11.93M |
|
$-12.77M |
|
$-12.74M |
|
90.05M |
|
90.05M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$78.54M |
|
-- |
|
$1.06M |
|
$79.59M |
|
$6.70M |
|
-- |
|
-- |
|
$6.70M |
|
|
Common Equity |
$72.90M |
$72.90M |
|
$72.90M |
|
74.81M |
|
| Cash Flow Statement Financials | |
$-20.27M |
|
$2.15M |
|
$-0.10M |
|
$56.49M |
|
$38.27M |
|
$-18.22M |
|
$10.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-20.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.37% |
|
-16.37% |
|
-14.99% |
|
-16.37% |
|
$0.97 |
|
$-0.23 |
|
$-0.23 |
|